Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ATOS
vs
S&P 500
ATOS
S&P 500
Over the past 12 months, ATOS has underperformed S&P 500, delivering a return of -82% compared to S&P 500's +13% growth.
Stocks Performance
ATOS vs S&P 500
Performance Gap
ATOS vs S&P 500
Performance By Year
ATOS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Atossa Therapeutics Inc
Glance View
Atossa Therapeutics is a clinical-stage drug developer focused on breast cancer and other breast health conditions. The company works on treatments meant to be taken by patients, with a pipeline centered on medicines that can reduce cancer risk, treat early disease, or help in combination with other therapies. It does not sell consumer products; its business is built around advancing drug candidates through research and clinical testing. Its main customers are not end users in the usual sense, but doctors, hospitals, and eventually patients if a drug is approved. Atossa aims to make money by developing therapies that can be licensed, partnered, or sold after regulatory approval, rather than by manufacturing large amounts of medicine itself. In practice, most of its value comes from turning lab and clinical work into a drug program that a larger pharmaceutical company or the healthcare system can use. What makes Atossa different is its narrow focus on breast cancer biology, especially hormone-driven disease. That gives the company a specialized role in a very large treatment area: it tries to find targeted medicines that fit specific patient groups instead of broad, all-purpose oncology drugs. This makes it a research-driven biotech company where the main challenge is proving that its drug candidates are safe and effective enough to become real treatments.